Randomised controlled trial of the efficacy of adding intravenous benzylpenicillin to intravenous flucloxacillin in the treatment of lower limb cellulitis

Submission date	Recruitment status No longer recruiting	Prospectively registered	
30/09/2004		☐ Protocol	
Registration date 30/09/2004	Overall study status Completed	Statistical analysis plan	
		[X] Results	
Last Edited 23/09/2009	Condition category Skin and Connective Tissue Diseases	[] Individual participant data	

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Ms Penelope Shirlaw

Contact details

Oral Medicine Department
22nd Floor, Guy's Tower
Guy's Hospital
St Thomas Street
London
United Kingdom
SE1 9RT
+44 (0)20 7188 4399
pepe.shirlaw@gstt.sthames.nhs.uk

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

N0013101031

Study information

Scientific Title

Study objectives

Does the addition of benzylpenicillin shorten the duration of stay of patients and/or decrease the number of beta-lactam therapy failures.

Please note that as of 23/09/09 inclusion and exclusion criteria for this trial have been updated.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Received from local medical ethics committee

Study design

Randomised double-blind placebo controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Cellulitis

Interventions

In non-penicillin allergic patients, after consent they will be randomised to receive one of 2 treatments:

- 1. Intravenous (IV) flucloxacillin 1g four times a day (gds) and IV benzylpenicillin 1.2 g gds
- 2. IV flucloxacillin 1g qds and IV placebo (N Saline) qds.

Intervention Type

Other

Phase

Not Specified

Primary outcome measure

Duration of stay, as determined by the number of 6 hourly doses of antibiotic the patient received prior to discharge.

Secondary outcome measures

Therapy failure rate

Overall study start date

01/10/2001

Completion date

01/04/2003

Eligibility

Key inclusion criteria

Current information as of 23/09/09:

- 1. Patients with lower limb cellulitis and who require admission
- 2. Initial diameter of cellulitis >100 mm
- 3. Able to understand spoken and written english

Initial information at time of registration:

Patients with lower limb cellulitis and who require admission

Participant type(s)

Patient

Age group

Adult

Sex

Both

Target number of participants

81 (intervention group: 41, control group: 40)

Key exclusion criteria

Added 23/09/09:

- 1. Known allergy to the study drugs
- 2. Known renal or hepatic impairment,
- 3. Random capillary glucose >13 mmol/l
- 4. Acute co-existent illness in the affected leg, such as deep venous thrombosis, or wound/abscess requiring operative debridement/repair.

Date of first enrolment

01/10/2001

Date of final enrolment

01/04/2003

Locations

Countries of recruitment

England

United Kingdom

Study participating centre Oral Medicine Department

London United Kingdom SE1 9RT

Sponsor information

Organisation

Department of Health

Sponsor details

Richmond House 79 Whitehall London United Kingdom SW1A 2NL

Sponsor type

Government

Website

http://www.dh.gov.uk/Home/fs/en

Funder(s)

Funder type

Hospital/treatment centre

Funder Name

Guy's and St Thomas' NHS Trust (UK)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/05/2005		Yes	No